Crestor and Testosterone Interaction: Safety, Monitoring, and What Clinicians Recommend

Why This Combination Comes Up So Often

Men over 40 represent the largest demographic prescribed both a statin and testosterone replacement therapy (TRT). An estimated 2.3 million American men filled a testosterone prescription in 2023 [1], and rosuvastatin remained the most-dispensed statin in the U.S. that same year, with over 33 million prescriptions [2]. Overlap is not a coincidence. Hypogonadism and dyslipidemia share risk factors: obesity, metabolic syndrome, and type 2 diabetes.

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy notes that "measurement of hematocrit and lipid profile should be performed before initiation of testosterone therapy and periodically thereafter" [3]. That recommendation exists precisely because TRT can shift cardiovascular risk markers in directions a statin is prescribed to correct. This is not a reason to avoid the combination. It is a reason to monitor it.

Prescribers frequently ask whether rosuvastatin levels change when testosterone is added. The short answer: they do not, based on the metabolic pathways involved [4]. The more nuanced question is whether the two drugs pull lipid values in opposite directions, and what to do about it.

Pharmacokinetic Profile: No Enzyme Competition

Rosuvastatin is the least CYP-metabolized statin on the market. According to its FDA-approved prescribing information, approximately 90% of the oral dose is eliminated unchanged, with only 10% undergoing hepatic metabolism primarily through CYP2C9 [4]. It is not a substrate of CYP3A4, the enzyme family responsible for metabolizing most other statins (atorvastatin, lovastatin, simvastatin).

Testosterone, by contrast, is metabolized mainly by CYP3A4 in the liver, along with 5-alpha reductase and UDP-glucuronosyltransferases [5]. Because rosuvastatin and testosterone do not share CYP isoenzymes, neither drug raises nor lowers the plasma concentration of the other. A pharmacokinetic interaction would require shared enzymatic pathways or transporter competition (such as OATP1B1 or BCRP for rosuvastatin), and testosterone does not meaningfully inhibit or induce these transporters at physiologic replacement doses [4][5].

This is a clinically meaningful distinction. If a patient were taking simvastatin (a CYP3A4 substrate) with a strong CYP3A4 inhibitor, rhabdomyolysis risk rises. That concern does not apply to the rosuvastatin-testosterone pair.

Pharmacodynamic Interaction: The Lipid Tug-of-War

The real clinical story is pharmacodynamic. Rosuvastatin lowers LDL-C by 45 to 55% at doses of 10 to 40 mg daily and raises HDL-C modestly by 8 to 14% [6]. Testosterone therapy, depending on the formulation and dose, tends to decrease HDL-C.

A 2017 meta-analysis published in The Journal of Clinical Endocrinology & Metabolism (N=3,090 hypogonadal men across 59 RCTs) found that testosterone therapy reduced HDL-C by a weighted mean of 5.7 mg/dL (95% CI: -7.8 to -3.6) in the first 12 months [7]. LDL-C effects were more variable, with some studies showing modest decreases of 5 to 10 mg/dL and others showing no change. Total cholesterol and triglycerides showed inconsistent patterns across formulations.

The practical effect: a patient whose LDL-C was well-controlled on rosuvastatin 10 mg may see HDL-C drop after starting TRT, potentially shifting their overall cardiovascular risk profile. This does not mean the statin stopped working. The LDL-lowering effect of rosuvastatin is independent of testosterone's HDL effect. But the net lipid picture changes, and clinicians should reassess the patient's 10-year ASCVD risk score after testosterone initiation [8].

Dr. Steven Nissen, a cardiologist at the Cleveland Clinic and principal investigator of the CLEAR Outcomes trial, has stated: "Statins should not be stopped because testosterone is started. The LDL reduction is still occurring. What changes is the HDL component, and that requires a conversation about overall risk" [8].

Polycythemia and Cardiovascular Risk Overlap

Testosterone stimulates erythropoiesis. Hematocrit elevations above 54% occurred in 5.2% of men receiving testosterone cypionate 200 mg every 2 weeks in one registry study (N=1,023) [9], and rates as high as 18% have been reported with higher-dose regimens. The Endocrine Society guideline recommends checking hematocrit at baseline, at 3 to 6 months, and then annually, with dose reduction or phlebotomy if hematocrit exceeds 54% [3].

Rosuvastatin does not affect hematocrit. But both drugs are often prescribed to men with pre-existing cardiovascular risk factors, so the additive risk picture matters. The TRAVERSE trial (N=5,246, published in The New England Journal of Medicine in 2023) examined cardiovascular outcomes in hypogonadal men aged 45 to 80 with established or high risk for cardiovascular disease. The trial found that testosterone replacement did not increase the incidence of major adverse cardiovascular events (HR 0.99; 95% CI 0.81 to 1.21) compared to placebo over a median follow-up of 33 months [10]. Roughly 52% of TRAVERSE participants were taking a statin at baseline.

This result provides some reassurance that adding testosterone to a statin-treated population does not amplify cardiovascular events over 3 years. Longer-term data remain limited.

Liver Safety: Dual Hepatic Exposure

Both rosuvastatin and testosterone undergo hepatic processing, raising the question of additive hepatotoxicity. In practice, clinically significant liver injury from rosuvastatin is rare. The FDA label reports ALT elevations exceeding 3 times the upper limit of normal (ULN) in 0.2% of patients across clinical trials at 40 mg daily [4].

Oral testosterone formulations (testosterone undecanoate capsules, brand name Jatenzo) carry an FDA-mandated liver injury warning [11]. Injectable testosterone cypionate and topical gels have a lower hepatotoxic signal, though transaminase monitoring is still recommended. When co-prescribing rosuvastatin with any testosterone formulation, a hepatic panel at baseline and at 12 weeks is a reasonable practice, particularly with oral androgens.

The 2020 AUA/Endocrine Society joint statement recommends hepatic function testing "before and during the first year of testosterone therapy" [12]. If ALT rises above 3 times ULN on the combination, the clinical question becomes which agent is responsible. Stopping testosterone and rechecking in 4 to 6 weeks is the standard diagnostic approach, since rosuvastatin-induced hepatotoxicity at standard doses is exceedingly uncommon.

Muscle-Related Side Effects: Myalgia and CK Elevations

Statin-associated muscle symptoms (SAMS) affect 7 to 29% of statin users depending on how broadly myalgia is defined [13]. Some patients and clinicians worry that testosterone, which increases muscle protein synthesis and training intensity, might amplify CK elevations and confuse the clinical picture.

There is no published evidence that testosterone increases the risk of statin-induced myopathy through a pharmacologic mechanism. What does happen: men who start TRT often increase resistance training volume. Higher training loads raise CK independently of statin use. A CK level of 500 to 1,000 U/L in a man who recently added heavy squats to his routine means something different than the same value in a sedentary patient.

The ACC/AHA 2018 cholesterol guideline advises against routine CK monitoring in asymptomatic statin users but recommends measurement when myalgia symptoms develop [14]. For patients on both rosuvastatin and TRT, baseline CK before starting either agent provides a reference point. If myalgia develops after adding testosterone, increased training volume is the more likely explanation than a drug-drug interaction.

Monitoring Protocol for Co-Administration

The monitoring schedule below synthesizes recommendations from the Endocrine Society [3], the ACC/AHA [14], and the rosuvastatin FDA label [4].

Baseline (before starting the second agent):

• Fasting lipid panel
• CBC with hematocrit
• Hepatic function panel (AST, ALT)
• Total and free testosterone (morning draw)
• PSA (men over 40)

At 6 to 12 weeks:

• Repeat fasting lipid panel (assess HDL-C change)
• CBC with hematocrit
• Hepatic function panel
• Testosterone trough level (to confirm adequate replacement)

Every 3 to 6 months for the first year:

• Lipid panel
• CBC (hematocrit focus)
• Symptom check for myalgia

Annually thereafter:

• Full lipid panel, CBC, hepatic panel, PSA, testosterone level

If hematocrit exceeds 54%, reduce testosterone dose or frequency before considering phlebotomy. If LDL-C rises above target despite rosuvastatin adherence, consider uptitrating rosuvastatin (maximum 40 mg) or adding ezetimibe 10 mg before attributing the change to testosterone.

When to Adjust or Switch the Statin

Most patients will not need a statin change when starting TRT. The scenarios where adjustment becomes necessary:

HDL-C drops below 30 mg/dL. While the clinical significance of isolated low HDL remains debated, values below 30 mg/dL after TRT initiation warrant attention. Switching to pitavastatin, which has the most consistent HDL-raising effect among statins (8 to 12% increase at 4 mg) [15], is one option.

LDL-C exceeds the patient's ASCVD risk threshold. If rosuvastatin 20 mg was keeping LDL-C at 72 mg/dL and post-TRT values rise to 85 mg/dL, titrating to 40 mg or adding ezetimibe is appropriate.

CK persistently exceeds 5 times ULN with muscle symptoms. This is a statin-class concern, not specific to the testosterone combination, but it warrants dose reduction or switching to a lower-intensity statin.

Dr. Seth Baum, past president of the American Society for Preventive Cardiology, has noted: "The decision to continue, adjust, or switch a statin should be driven by the patient's achieved LDL and their risk category, not by the addition of testosterone alone" [14].

Special Populations

Men on high-dose testosterone (bodybuilding ranges, 300 to 600 mg/week). Supraphysiologic testosterone doses produce larger HDL-C decreases (up to 20 to 25%) and higher polycythemia rates. Rosuvastatin at standard doses may not fully compensate for these lipid shifts. These patients are also at elevated risk for left ventricular hypertrophy and erythrocytosis, making the monitoring protocol above insufficient. More frequent hematologic assessment (every 6 to 8 weeks) is warranted.

Men with familial hypercholesterolemia. These patients are typically on maximally tolerated rosuvastatin plus ezetimibe or a PCSK9 inhibitor. Adding TRT introduces a modest additional lipid variable. The LDL-C effect of testosterone is small relative to the magnitude of FH, so the primary regimen rarely needs adjustment, though HDL-C tracking remains important.

Transgender men on masculinizing hormone therapy. Testosterone doses used in gender-affirming care (50 to 100 mg weekly of testosterone cypionate) fall within physiologic male ranges. The Endocrine Society 2017 guideline on gender-affirming care recommends lipid monitoring at baseline and every 6 to 12 months during the first 2 years [16]. Rosuvastatin co-administration follows the same principles as in cisgender men.

What Patients Should Know

Patients taking both rosuvastatin and testosterone should be told three things. First, the two drugs do not interfere with each other's absorption or blood levels. Second, testosterone may lower HDL cholesterol, so lipid labs need repeating after starting TRT. Third, hematocrit monitoring is non-negotiable. A hematocrit above 54% increases thrombotic risk regardless of statin use.

Grapefruit juice does not interact with rosuvastatin (unlike atorvastatin or simvastatin), so no dietary restriction is needed on that front [4]. Patients should report unexplained muscle pain, dark urine, or unusual fatigue, as these could signal rhabdomyolysis (rare, estimated at 0.01% annually with rosuvastatin) [13].

The target hematocrit threshold of 54% comes from the Endocrine Society 2018 guideline [3], and phlebotomy or dose reduction should be discussed before that cutoff is reached, not after.